Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ETHK Labs's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.10.
During the past 12 months, the average EBIT per Share Growth Rate of ETHK Labs was -57.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -22.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ETHK Labs's EBIT per Share or its related term are showing as below:
HKSE:01931'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -22.3 Med: 16.2 Max: 97.2
Current: -22.3
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of ETHK Labs was 97.20% per year. The lowest was -22.30% per year. And the median was 16.20% per year.
HKSE:01931's 3-Year EBIT Growth Rate is ranked worse than 88.57% of 105
companies
in the Medical Distribution industry
Industry Median: 4
vs HKSE:01931: -22.30
ETHK Labs's EBIT for the
six
months ended in Dec. 2025 was HK$60 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ETHK Labs EBIT per Share Related Terms
ETHK Labs EBIT per Share Historical Data
* Premium members only.
The historical data trend for ETHK Labs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETHK Labs (HKSE:01931) has a EBIT per Share of HK$0.10 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ETHK Labs and its competitors. According to the industry distribution chart, ETHK Labs ranks #93 out of 105 companies in the Medical Distribution industry, placing it in the top 88.6%.
Is ETHK Labs' EBIT per Share too high?
ETHK Labs' current EBIT per Share is HK$0.10. Based on the distribution chart, ETHK Labs ranks #93 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, ETHK Labs has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ETHK Labs' EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ETHK Labs ranks #93 out of 105 companies for EBIT per Share. This places ETHK Labs in the lower half of its industry. The industry median EBIT per Share is 4.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.00, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ETHK Labs and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ETHK Labs's current EBIT per Share is HK$0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ETHK Labs stock overvalued right now?
Based on GuruFocus' analysis, ETHK Labs (HKSE:01931) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.37, compared to a current price of HK$0.59 — trading 57.3% below its estimated fair value. The current EBIT per Share is HK$0.10. ETHK Labs' overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ETHK Labs (HKSE:01931), the current EBIT per Share is HK$0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ETHK Labs (HKSE:01931) Overvalued in 2026?
Based on GuruFocus' analysis, ETHK Labs stock appears to be undervalued.
The current stock price of HK$0.59 is trading 57.3% below its estimated GF Value™ of HK$1.37.
GuruFocus considers ETHK Labs to be Possible Value Trap.
Key valuation signals for HKSE:01931:
EBIT per Share: HK$0.10
GF Value™: HK$1.37 vs. price of HK$0.59 (57.3% below fair value)
No single metric tells the full story. See the HKSE:01931 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ETHK Labs Inc is engaged in the distribution, after-sales service, and development of in-vitro diagnostic (IVD) products in China. The company operates through three business segments: Distribution Business, After-sales Services, and Self-branded Products Business. It distributes IVD analysers, reagents, and consumables to hospitals and healthcare institutions, provides maintenance and installation services for diagnostic equipment, and develops and sells self-branded IVD analysers and reagents. The company generates the majority of its revenue from Mainland China.
74GF Score
Get the complete analysis for HKSE:01931
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01931 has been successfully added to your 
